121268-17-5NCCCC(O)(P(=O)([O-])O)P(=O)(O)O.O.O.O.[Na+]DCSBSVSZJRSITC-UHFFFAOYSA-MAlendronate sodium trihydrate is a hydride that is the trihydrate of alendronate sodium. It has a role as an EC 2.5.1.1 (dimethylallyltranstransferase) inhibitor and a bone density conservation agent. It is a hydrate and an organic sodium salt. It contains an alendronate(1-).
121268-17-5DTXSID7047801CHEMBL2367465、CHEMBL675CHEBI:2566FDA approved drugs -> Active ingredient
EMA approved medicines: Human medicine
EMA approved medicines: Human medicine
FDA approved drugs -> Active ingredient
White Crystalline Solid
안전 정보는 참고용이며, 공급업체의 물질안전보건자료(SDS), 관련 법규 및 전문가 평가를 대체하지 않습니다.
This chemical does not meet GHS hazard criteria for 1.8% (2 of 110) of reports.
Danger
H302 (98.2%): Harmful if swallowed [Warning Acute toxicity, oral]
P203, P260, P261, P264, P264+P265, P270, P271, P280, P301+P317, P302+P352, P304+P340, P305+P354+P338, P317, P318, P319, P321, P330, P332+P317, P362+P364, P403+P233, P405, and P501 (click each P-code to see the statement)
Aggregated GHS information provided per 110 reports by companies from 11 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.
Warning
Acute Tox. 4 (98.2%)
Acute Tox. 4 (100%)
Relative to an intravenous (IV) reference dose, the mean oral bioavailability of alendronate in women was 0.7% for doses ranging from 5 to 40 mg when administered after an overnight fast and two hours before a standardized breakfast. Oral bioavailability of the 10 mg tablet in men (0.59%) was similar to that in women (0.78%) when administered after an overnight fast and 2 hours before breakfast.
The action of Alendronate on bone tissue is based partly on its affinity for hydroxyapatite, which is part of the mineral matrix of bone. Alendronate also targets farnesyl pyrophosphate (FPP) synthase. Nitrogen-containing bisphosphonates (such as pamidronate, alendronate, risedronate, ibandronate and zoledronate) appear to act as analogues of isoprenoid diphosphate lipids, thereby inhibiting FPP synthase, an enzyme in the mevalonate pathway. Inhibition of this enzyme in osteoclasts prevents the biosynthesis of isoprenoid lipids (FPP and GGPP) that are essential for the post-translational farnesylation and geranylgeranylation of small GTPase signalling proteins. This activity inhibits osteoclast activity and reduces bone resorption and turnover. In postmenopausal women, it reduces the elevated rate of bone turnover, leading to, on average, a net gain in bone mass.
There is no evidence that alendronate is metabolized in humans or animals. Route of Elimination: Following a single IV dose of [14C]alendronate, approximately 50% of the radioactivity was excreted in the urine within 72 hours and little or no radioactivity was recovered in the feces. Half Life: >10 years
ALENDRONATE SODIUM
Diphosphonates [CS]; Bisphosphonate [EPC]
ALENDRONATE SODIUM TABLET
Bisphosphonate [EPC]; Diphosphonates [CS]
용도Alendronate sodium trihydrate is used as a bone resorption inhibitor, farnesyl diphosphate synthase inhibitor and CD45 protein tyrosine phosphatase inhibitor. A robust inhibitor of bone resorption that induces apoptosis. Alendronate inhibits the migration and invasion of PC-3 cells (sc-2220) by interfering with the mevalonate pathway. Additionally, Alendronate, Sodium Salt is an inhibitor of CD45RC and MMP.
일반 설명Alendronate Sodium, an aminobisphosphonate compound, has been effectively used for the treatment of osteolysis, Paget′s disease and osteoporosis.
Drug Induced Liver Injury Rank (DILIrank 2.0)
Alendronate sodium
vLess-DILI-concern
0
No match
DOI:10.1016/j.drudis.2016.02.015
정의ChEBI: A hydride that is the trihydrate of alendronate sodium